Solid Biosciences’ (SLDB) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Solid Biosciences (NASDAQ:SLDB) in a report released on Friday morning,Benzinga reports. They currently have a $19.00 target price on the stock.

A number of other research firms also recently issued reports on SLDB. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Solid Biosciences in a report on Thursday, January 22nd. Wedbush reiterated an “outperform” rating and issued a $14.00 target price on shares of Solid Biosciences in a report on Wednesday, March 11th. Chardan Capital reissued a “buy” rating and set a $15.00 price target on shares of Solid Biosciences in a research report on Thursday, March 12th. Finally, Citigroup restated a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Solid Biosciences Stock Down 1.3%

SLDB stock opened at $7.03 on Friday. Solid Biosciences has a twelve month low of $2.41 and a twelve month high of $8.72. The stock’s 50 day moving average is $6.43 and its 200-day moving average is $5.80. The firm has a market capitalization of $547.71 million, a PE ratio of -3.48 and a beta of 2.64.

Solid Biosciences (NASDAQ:SLDB) last announced its earnings results on Thursday, March 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.01. On average, equities research analysts anticipate that Solid Biosciences will post -2.84 earnings per share for the current fiscal year.

Insider Transactions at Solid Biosciences

In other news, COO David T. Howton sold 37,771 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total transaction of $243,245.24. Following the completion of the sale, the chief operating officer directly owned 116,753 shares of the company’s stock, valued at $751,889.32. This trade represents a 24.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jessie Hanrahan sold 26,535 shares of Solid Biosciences stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $170,885.40. Following the sale, the insider owned 82,675 shares in the company, valued at $532,427. The trade was a 24.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 597,672 shares of company stock worth $3,816,546. Company insiders own 13.63% of the company’s stock.

Institutional Trading of Solid Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc grew its position in shares of Solid Biosciences by 208.6% during the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock valued at $29,000 after acquiring an additional 4,063 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock worth $33,000 after purchasing an additional 4,534 shares during the period. Creative Planning purchased a new position in Solid Biosciences in the second quarter valued at approximately $57,000. Russell Investments Group Ltd. lifted its stake in Solid Biosciences by 142.0% in the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock valued at $63,000 after purchasing an additional 5,991 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its holdings in Solid Biosciences by 233.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock valued at $74,000 after purchasing an additional 10,585 shares during the period. Institutional investors own 81.46% of the company’s stock.

Trending Headlines about Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Guggenheim started coverage with a Buy and a $26 price target (implies ~272% upside from recent levels), giving formal street-level momentum and a large upside case for the stock. Guggenheim starts coverage (Benzinga)
• Positive Sentiment: Needham reaffirmed Buy with a $19 price target, signaling continued analyst conviction in the company’s clinical progress and longer-term value. Needham reaffirms buy (Benzinga)
• Positive Sentiment: Chardan reaffirmed its Buy rating and $15 target, adding to the cluster of upgrade/reaffirmation headlines that can attract investor attention and trading demand. Chardan reaffirms buy (TickerReport)
• Positive Sentiment: Solid reported positive interim Phase 1/2 INSPIRE data for SGT-003 at the 2026 MDA meeting; the readout highlights generally favorable tolerability in 41 dosed participants—this is the primary fundamental catalyst supporting higher valuations. SGT-003 interim data (GlobeNewswire)
• Neutral Sentiment: The company issued its Q4 and full-year 2025 results and broader business updates; the release contains operational context and program timelines that investors will parse for runway and development plans. Q4 & full-year 2025 results (FinanzNachrichten)
• Negative Sentiment: SLDB missed Q4 EPS expectations (reported -$0.53 vs. consensus -$0.48), underlining ongoing losses and near-term profitability risk that likely capped the stock’s upside today. Earnings press release (Quartr)

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.